Functional characterization of peptide transporters in MDCKII-MDR1 cell line as a model for oral absorption studies

International Journal of Pharmaceutics

Volumn 332, Issue 1-2, 2007, Pages 147-152

  Agarwal, Sheetal ^a   Jain, Ritesh ^a   Pal, Dhananjay ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Apical (AP); Basolateral (BL); Caco 2 cells; Gly Sar; Madin Darby canine kidney cells; MDCKII MDR1; MDCKII WT; P glycoprotein (P gp); Peptide transporter; Permeability; Transport; Uptake

Indexed keywords

CARRIER PROTEIN; GLYCOPROTEIN P; GLYCYLSARCOSINE;

ANIMAL CELL; APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL STRAIN; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG UPTAKE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CEPHALOSPORINS; DIPEPTIDES; DOGS; EPITHELIAL CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; KINETICS; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PRODRUGS; TIME FACTORS;

EID: 33846866495     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.09.056     Document Type: Article

References (20)

1. Endicott J.A., and Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58 (1989) 137-171
2. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62 (1993) 385-427
3. Guo A., Marinaro W., Hu P., and Sinko P.J. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab. Dispos. 30 (2002) 457-463
4. Irvine J.D., Takahashi L., Lockhart K., Cheong J., Tolan J.W., Selick H.E., and Grove J.R. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88 (1999) 28-33
5. Ito K., Kusuhara H., and Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharm. Res. 16 (1999) 225-231
6. Jain R., Majumdar S., Nashed Y., Pal D., and Mitra A.K. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization. Mol. Pharm. 1 (2004) 290-299
7. Jain R., Agarwal S., Majumdar S., Zhu X., Pal D., and Mitra A.K. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. Int. J. Pharm. 303 (2005) 8-19
8. Keogh J.P., and Kunta J.R. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur. J. Pharm. Sci. 27 (2006) 543-554
9. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.L., Turgeon D.K., Schmiedlin-Ren P., Brown M.B., Guo W., Rossi S.J., Benet L.Z., and Watkins P.B. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62 (1997) 248-260
10. Pal D., and Mitra A.K. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 78 18 (2006) 2131-2145 Epub 2006 Jan 25
11. Putnam W.S., Ramanathan S., Pan L., Takahashi L.H., and Benet L.Z. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J. Pharm. Sci. 91 (2002) 2622-2635
12. Rice A., Michaelis M.L., Georg G., Liu Y., Turunen B., and Audus K.L. Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors. J. Mol. Neurosci. 20 (2003) 339-343
13. Rodriguez-Proteau R., Mata J.E., Miranda C.L., Fan Y., Brown J.J., and Buhler D.R. Plant polyphenols and multidrug resistance: effects of dietary flavonoids on drug transporters in Caco-2 and MDCKII-MDR1 cell transport models. Xenobiotica 36 (2006) 41-58
14. Rouquayrol M., Gaucher B., Roche D., Greiner J., and Vierling P. Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers. Pharm. Res. 19 (2002) 1704-1712
15. Rousselle C., Clair P., Lefauconnier J.M., Kaczorek M., Scherrmann J.M., and Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 57 (2000) 679-686
16. Tang F., Horie K., and Borchardt R.T. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?. Pharm. Res. 19 (2002) 765-772
17. Terada T., Sawada K., Ito T., Saito H., Hashimoto Y., and Inui K. Functional expression of novel peptide transporter in renal BL membranes. Am. J. Physiol. Renal. Physiol. 279 (2000) F851-F857
18. Varma M.V., Ashokraj Y., Dey C.S., and Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res. 48 (2003) 347-359
19. Watkins P.B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27 (1997) 161-170
20. Williams G.C., Knipp G.T., and Sinko P.J. The effect of cell culture conditions on saquinavir transport through, and interactions with MDCKII cells overexpressing hMDR1. J. Pharm. Sci. 92 (2003) 1957-1967